Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - 9 months ended Sep. 30, 2017 - USD ($)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Series B Redeemable Convertible Preferred Stock [Member]
Beginning Balance at Dec. 31, 2016							$ 0
Beginning Balance (in shares) at Dec. 31, 2016							0
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts							$ 6,276,228
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts (in shares)							15,656
Accretion of Series B redeemable convertible preferred stock							$ 1,962,072
Ending Balance at Sep. 30, 2017							$ 8,238,300
Ending Balance (in shares) at Sep. 30, 2017							15,656
Beginning Balance at Dec. 31, 2016	$ 32,207,323	$ 5,993	$ 692	$ 71,034,899	$ (31,259,449)	$ (7,574,812)
Beginning Balance (in shares) at Dec. 31, 2016		599,285	6,917,204
Stock based compensation	905,230			905,230
Vesting and accelerated vesting of restricted stock	231,900		$ 5	231,895
Vesting and accelerated vesting of restricted stock (in shares)			48,988
Exercises of stock options	16,455		$ 20	16,435
Exercises of stock options (in shares)			200,657
Warrant issuance, net of issuance costs	548,956			548,956
Conversion of Series B convertible preferred stock into common stock		$ (5,993)	$ 60	5,933
Conversion of Series B convertible preferred stock into common stock (in shares)		(599,285)	599,285
Conversion of convertible notes and accrued interest into common stock	3,645,424		$ 32	3,645,392
Conversion of convertible notes and accrued interest into common stock (in shares)			316,734
Warrant exercises			$ 66	(66)
Warrant exercises (in shares)			660,715
Issuance of common stock for the acquisition of subsidiaries	44,742,737		$ 688	44,742,049
Issuance of common stock for the acquisition of subsidiaries (in shares)			6,883,498
Issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs and discounts	3,223,853			3,223,853
Accretion of Series B redeemable convertible preferred stock	(1,962,072)			(1,962,072)
Foreign currency translation adjustments	2,864,839					2,864,839
Net loss	(37,594,401)				(37,594,401)
Ending Balance at Sep. 30, 2017	$ 48,830,244		$ 1,563	$ 122,392,504	$ (68,853,850)	$ (4,709,973)
Ending Balance (in shares) at Sep. 30, 2017			15,627,081